Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Air Pollutant Might Be to Blame for NDMA Formation in Metformin: Towa Paper
Over the past years, a series of recalls have been triggered globally by cancer-causing impurities detected in popular medicines. Among them is metformin, and the latest research shows that a carcinogen found in the diabetes drug was likely produced when…
To read the full story
Related Article
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- Towa Launches Task Force to Tackle Nitrosamine Impurities, Share Solutions with Peers
July 24, 2025
- Towa Develops Analytical Method for Nitrosamine in Antidepressant Duloxetine
March 12, 2024
- Metformin Cancer Risk Acceptable at 1 in 550,000 Patients: NIHS Assessment
October 1, 2020
- Towa, Nichi-Iko Recalling Some Metformin Products over Carcinogen Risks, Follow 2 Makers
September 17, 2020
- Sumitomo Dainippon, Nihon Generic Pulling Some Metformin Products over Carcinogen Risks
April 28, 2020
- Metformin Manufacturers Ordered to Test for Potential Carcinogen Contamination
December 10, 2019
BUSINESS
- M3’s MR-kun Hit by Data Breach, Pharma Staff and Doctors Exposed
October 16, 2026
- Santen Hits 93% Weekly AI Adoption in R&D, Digitizes Truckload of Research Records
October 16, 2026
- Medley Reports Cyberattack, Patient Data at Risk at Up to 787 Facilities
October 16, 2026
- Takeda’s TAK-881 Shaves 56 Minutes Off Infusion Time vs HyQvia
October 16, 2026
- UCB Japan Recalls Cimzia Over Needle Retraction Defect
October 16, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…